ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?

@article{Toyokawa2014ALKIW,
  title={ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?},
  author={Gouji Toyokawa and Takashi Seto},
  journal={Clinical lung cancer},
  year={2014},
  volume={15 5},
  pages={313-9}
}
Genetic insight into the pathogenesis of lung cancer has paved the way for a new era in its treatment. Recently, anaplastic lymphoma kinase (ALK) has been identified as exerting a potent transforming effect through genetic rearrangement in patients with lung cancer. Preclinical and single-arm phase I studies have shown that patients with ALK-rearranged non-small cell lung cancer (NSCLC) can be successfully treated with crizotinib. Furthermore, a phase III randomized study indicated that… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Similar Papers

Loading similar papers…